Biosimilar Contract Manufacturing Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook 2026-2030

Biosimilar contract manufacturing refers to third-party organizations (CDMOs) that handle process development, cell line engineering, scale-up, GMP production, aseptic fill-finish and quality analytics for biosimilar developers. The segment sits inside the broader pharmaceutical contract manufacturing industry, which itself was valued near USD 210 billion in 2025, and biosimilars are consistently flagged as one of its faster-growing sub-categories. Demand is concentrated where complex biologics, such as monoclonal antibodies, recombinant proteins and fusion proteins, require mammalian cell culture, viral clearance validation and high-containment facilities that most sponsors prefer to outsource.

• •2025 market size estimated at approximately USD 9.39 billion, with a forecast CAGR of about 14.87%
• •Core service scope spans cell line development, upstream/downstream processing, fill-finish and analytical characterization
• •Independent estimates for 2025 range from roughly USD 8.4B to USD 12.0B depending on scope and methodology

Patent cliffs on blockbuster monoclonal antibodies and other biologics are creating a steady pipeline of biosimilar targets that sponsors lack the internal capacity to manufacture efficiently. National health systems and private payers in the U.S. and Europe are pushing for lower-cost alternatives to high-priced reference biologics, while regulators in these and other major markets have established clearer approval pathways that reduce technical risk for biosimilar developers. In parallel, biologics production requires mammalian cell-culture suites, single-use bioreactors and specialized fill-finish capacity that are capital-intensive to build, so smaller biosimilar sponsors continue to outsource the majority of their manufacturing to CDMOs.

• •Major reference-biologic patent expiries opening large addressable indications to biosimilar competition
• •Regulatory pathway maturation (EMA, FDA and other established frameworks) lowering approval uncertainty
• •High capital intensity of large-molecule GMP facilities incentivizing sponsor reliance on CDMO capacity

By service type, demand is split across process development, commercial-scale manufacturing and fill-finish/analytical services, with commercial-scale GMP production typically representing the largest revenue share. By molecule, monoclonal antibodies dominate, followed by recombinant proteins and other complex biologics such as fusion proteins and peptides. Geographically, Europe historically leads in biosimilar approvals and adoption, North America represents the largest single revenue pool given drug pricing and payer dynamics, and Asia-Pacific (notably South Korea, India, China and Singapore) is the fastest-growing region as regional CDMOs scale up mammalian cell-culture capacity.

• •Mammalian-cell monoclonal antibody manufacturing accounts for the majority of outsourced volume
• •Europe leads in approved biosimilars; North America is the largest revenue market by value
• •Asia-Pacific is the fastest-expanding region as Korean, Indian and Chinese CDMOs add GMP capacity

What are the recent trends and outlook?

Through the latter half of the 2020s, the market is expected to ride a continuing wave of biosimilar approvals in oncology, autoimmune disease and ophthalmology, with commercial manufacturing demand scaling in step with product launches. CDMOs are investing in additional single-use bioreactor capacity, high-titer process intensification and integrated fill-finish lines to compress development timelines and reduce cost-of-goods. At the same time, geopolitical discussion around concentration of biologics manufacturing in specific regions is encouraging some sponsors and governments to qualify dual-source CDMOs, a dynamic likely to support continued capacity expansion across both Western and Asian providers.

• •Capacity expansion in single-use bioreactors and integrated fill-finish is accelerating to meet commercial launch demand
• •Process intensification and high-titer expression systems are reducing per-batch cost-of-goods
• •Sponsors are increasingly qualifying dual-source CDMOs to mitigate geographic supply concentration risk